Translator: Theresa by Vancouver Sailing Farm, Canada

The best way to expose a lie is to analyze the same problem with the logic of the lie itself.

Pharmaceutical companies and politicians tout the COVID-19 vaccine to prevent infections and reduce deaths. They are all based on the same algorithm: (Unvaccinated Covid-19 confirmed rate – vaccinated Covid-19 confirmed rate) / Unvaccinated Covid-19 confirmed rate.

Pfizer/BioNTech claims to the public that the Covid-19 vaccine is 95% effective, AstraZeneca claims the Covid-19 vaccine (coronavirus or CCP virus vaccine) is 70% effective, and Moderna claims the Covid-19 vaccine is 98% effective %, and they are all based on the same algorithm: (Unvaccinated Covid-19 confirmed rate – vaccinated Covid-19 confirmed rate) / Unvaccinated Covid-19 confirmed rate.

For example, an article “Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study” published on the official website of Pfizer on April 1, 2021, stated that More than 46,307 participants aged 16 years and older were assessed for Covid-19 vaccine safety, and more than 12,000 vaccinated participants were followed for at least six months after the second dose, concluding that there is no significant risk to the vaccine as of 2021. Analysis of 927 confirmed cases of COVID-19 observed in its pivotal Phase 3 study on March 13, 2019 shows that BNT162b2 is highly effective in preventing COVID-19 virus infection for up to 7 days after second dose of vaccine The COVID-19 vaccine efficacy rate was observed to be 91.3% within 6 months, and the vaccine was 100% effective in preventing severe disease from COVID-19 as defined by the U.S. Centers for Disease Control and Prevention (CDC), and in preventing the U.S. Food and Drug Administration (FDA) ) was 95.3% effective in terms of severe disease defined by COVID-19.

The article said that after clinical trials of the same number of placebo and vaccine groups, among a total of 927 confirmed cases of COVID-19 infection, there were 850 cases in the placebo group and 77 cases in the BNT162b2 group, corresponding to a vaccine efficacy of 91.3%. The basis is:

Pfizer/BioNTech BNT162b2 COVID-19 vaccine efficacy rate = (placebo group COVID-19 infection confirmed rate – vaccine group COVID-19 infection confirmed rate)/placebo group COVID-19 infection confirmed rate = (850-77)/850= 90.94%, according to the revision of clinical medical records, the effective rate of Pfizer/BioNTech BNT162b2 COVID-19 vaccine was determined to be 91.3%.

Thirty-two cases of CDC-defined severe disease were observed in the placebo group, but not in the BNT162b2-vaccinated group, indicating that the vaccine was 100% effective against CDC-defined severe disease. It is calculated based on:

Pfizer/BioNTech BNT162b2 COVID-19 vaccine against CDC-defined severe disease rate = (placebo group COVID-19 severe disease rate – vaccine group COVID-19 severe disease rate)/placebo group COVID-19 severe disease rate = (32-0)/32=100%, confirming that the Pfizer/BioNTech BNT162b2 COVID-19 vaccine is 100% effective against CDC-defined severe disease.

According to the FDA definition, 21 severe cases of COVID-19 infection were observed in the placebo group, while 1 severe case of COVID-19 infection was observed in the BNT162b2 vaccinated group, indicating an FDA-defined efficacy of 95.3% in preventing severe cases of COVID-19 infection.

The calculation is based on:

Pfizer/BioNTech BNT162b2 COVID-19 vaccine efficacy rate against FDA-defined severe disease = (placebo group COVID-19 severe disease rate – vaccine group COVID-19 severe disease rate) / placebo group COVID-19 severe disease rate = (21-1)/21=95.3%, confirming that the Pfizer/BioNTech BNT162b2 COVID-19 vaccine is 95.3% effective against FDA-defined severe disease.

Another article “Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints” published on November 8, 2020 on Pfizer’s official website stated that the Phase 3 clinical trial of BNT162b2 was conducted on July 27. Initially, 43,661 participants were recruited from approximately 150 clinical trial sites in the United States, Germany, Turkey, South Africa, Brazil, and Argentina, with an average allocation of 43,661 subjects to the placebo and vaccine groups (approximately 21,830 subjects each) . A total of 170 confirmed cases of infection with COVID-19 were evaluated, of which 162 were observed in the placebo group and 8 in the vaccine group, leading to the Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine starting 28 days after the first dose 95% effectiveness in preventing infection with the COVID-19 virus.

In the placebo group that did not receive the Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine, 162 people became infected with the COVID-19 virus and developed symptoms. In the group that received the actual vaccine, that number was only eight.

Therefore, the percentage of the placebo group infected with the COVID-19 virus = 162/21830 = 0.74%. Percentage of COVID-19 virus infection in the group vaccinated with Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine = 8/21830 = 0.04%.

Pfizer was able to claim that injection of their Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine was effective in preventing infection with the COVID-19 virus = (0.74%-0.04%)/0.74%=95%.

Weekly report from Public Heath England, starting with the 36th COVID-19 vaccine surveillance report: 9 September 2021 (week 36) , both the number of people infected with the COVID-19 virus per 100,000 unvaccinated people in the previous 4 weeks and the number of people infected with the COVID-19 virus per 100,000 vaccinated people in the previous 4 weeks.

This provides the best basis for analyzing the effectiveness of full vaccination against Covid-19 infection.

The chart is showing《COVID-19 vaccine surveillance report: 9 September 2021 (week 36)》Page 14Table 4. COVID-19 cases by vaccination status between week 32 and week 35 2021

Based on the data in the table above, the effectiveness of complete vaccination against the COVID-19 virus in weeks 32-35 reported in the 36th report for preventing COVID-19 infection can be calculated, and the results are as follows:

The third column from the bottom of the table above is the confirmed rate of CCP virus infection in the first four weeks per 100,000 fully vaccinated people, and the second column from the bottom is the confirmed rate of CCP virus infection in the first four weeks per 100,000 people who have never been vaccinated. . The number in the calculation result is black, which means that the infection rate of the CCP virus is lower than that of the unvaccinated, and the red means that the infection rate of the CCP virus is higher than that of the unvaccinated. At this time, the vaccine cannot prevent the infection, but increases the infection.

According to this idea, the effectiveness of fully vaccinated against COVID-19 virus every four weeks for the 37th to 51st period in 2021 and the first period of this year in preventing COVID-19 infection was calculated. The statistical results are as follows:

If the vaccine effectiveness is positive, it means that the vaccine does reduce infection. If the vaccine efficacy rate is 0, the vaccine does not work. If the vaccine efficacy rate is negative, it indicates the degree of damage to the body’s own immune system or the degree of increased infection by the vaccine.

According to the data in the table above, for people over the age of 18, most people are less likely to be initially infected with the CCP virus after being vaccinated, but for people over the age of 40, the vaccination immediately showed serious side effects.

Vaccines become less effective over time, until significant side effects (shown in red) are evident, and the fully vaccinated population is more susceptible to infection than the unvaccinated population.

Reference:

Author: Michael.Tonny by Vancouver Sailing Farm, Canada

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

Official UK Government data suggests Fully Vaccinated Brits will develop Acquired Immunodeficiency Syndrome by the end of February 2022

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

COVID-19 vaccine weekly surveillance reports (weeks 39 to 1, 2021 to 2022)

UK Government reports suggest the Fully Vaccinated are rapidly developing Acquired Immunodeficiency Syndrome, and the Immune System decline has now begun in Children

News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine

Study: COVID-19 Vaccine Can Destroy Your Immune System

Reports of shingles outbreaks not directly linked to COVID-19 vaccine

Fauci: Amount of Virus in COVID-19 Breakthrough Delta Cases ‘Almost Identical’ to Unvaccinated

Comparing age adjusted all-cause mortality rates in England between vaccinated and unvaccinated

Edit: Gerald Garwood  Publish: 文敏